MedTrace Logo

LUMINIST: LUng Cancer Molecular Insights Non Interventional Study

NCT02300831 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 770

Last updated 2017-07-14

No results posted yet for this study

Summary

The recent development of therapies targeting specific biomarkers mutations is changing the standards of care and prognosis of patients with advanced NSCLC, but very few data are currently available on those emerging biomarkers. In addition, the correlation of biomarkers with patients' clinical outcomes in a standard of care setting is poorly understood. This study aims to address that need.

Conditions

Interventions

OTHER

Data Collection

Non interventional prospective data collection

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Gabriella Mariani, MD · AstraZeneca UK, MSD

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-01
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Australia
  • Austria
  • Belgium
  • Bulgaria
  • Canada
  • Chile
  • France
  • Germany
  • Hungary
  • Israel
  • Italy
  • Mexico
  • Netherlands
  • Peru
  • Poland
  • Portugal
  • Romania
  • Russia
  • Spain
  • Sweden
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02300831 on ClinicalTrials.gov